CD79b antibody | AT107-2
Filter by Application:F Reset
|Rat anti Mouse CD79b antibody, clone AT107-2 recognizes a cytoplasmic region of mouse B-cell antigen receptor complex-associated protein beta chain, also known as B-cell-specific glycoprotein B29, Ig-beta, or Immunoglobulin-associated B29 protein. CD79b is a 228 amino acid, including a 26 signal peptide ~40 kDa type I single pass transmembrane glycoprotein. CD79b is expressed by B lymphocytes and associates with CD79a to form a heterodimer, non-covalently linked to surface immunoglobulin, forming the B-cell receptor (BCR) complex. Rat anti Mouse CD79b antibody, clone AT107-2 also recognizes a homologous region of human CD79b.|
- Target Species
- Species Cross-Reactivity
Target Species Cross Reactivity Human Rat Pig Dog Chicken Koala Tasmanian Devil Cat
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- TRIS buffered saline
- Preservative Stabilisers
- 0.09% sodium azide (NaN3)
- Carrier Free
- Peptide containing 20 amino acid residues from mouse CD79b conjugated to Keyhole Limpet Hemocyanin (KLH).
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised rat were fused with cells of the mouse NS-1 myeloma cell line.
- For research purposes only
- 12 months from date of despatch
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
|Application Name||Verified||Min Dilution||Max Dilution|
|Flow Cytometry 1||1/500||1/1000|
- 1 Membrane permeabilization is required for this application. The use of Leucoperm (Product Code BUF09) is recommended for this purpose.
- Flow Cytometry
- Use 10μl of the suggested working dilution to label 1x106 cells in 100μl
References for CD79b antibody
Dornan, D. et al. (2009) Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma.
Blood. 114: 2721-9.
Vendel,A.C. et al (2009) B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK.
J Immunol. 182: 1509-17
Poggi, A. et al (2017) Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma.
Vet Comp Oncol. 15 (2): 431-40.
Kreiss, A. et al. (2009) A histological and immunohistochemical analysis of lymphoid tissues of the Tasmanian devil.
Anat Rec (Hoboken). 292: 611-20.
Lau, Q. et al. (2012) Expression and in vitro upregulation of MHCII in koala lymphocytes.
Vet Immunol Immunopathol. 147: 35-43.
Kandasamy S et al. (2014) Prenatal vitamin A deficiency impairs adaptive immune responses to pentavalent rotavirus vaccine (RotaTeq®) in a neonatal gnotobiotic pig model.
Vaccine. 32 (7): 816-24.
Whitney, J.L. et al. (2016) Immunohistochemical Analysis of Leucocyte Subsets in the Sinonasal Mucosa of Cats with Upper Respiratory Tract Aspergillosis.
J Comp Pathol. 155 (2-3): 130-40.
McCurdy, P. et al. (2014) Acute lymphoblastic leukemia in a pygmy hippopotamus (Hexaprotodon liberiensis).
J Zoo Wildl Med. 45 (4): 906-10.
View The Latest Product References
Allan, J.N. et al. (2019) CD79b Expression in Richter's Transformation
Blood. 134 (Supplement_1): 4279.
Thalheim, L. et al. (2013) Lymphoma immunophenotype of dogs determined by immunohistochemistry, flow cytometry, and polymerase chain reaction for antigen receptor rearrangements.
J Vet Intern Med. 27 (6): 1509-16.
Ouyang, K. et al. (2015) Evaluation of humoral immune status in porcine epidemic diarrhea virus (PEDV) infected sows under field conditions.
Vet Res. 46: 140.
Bennett, A.L> et al. (2017) Canine acute leukaemia: 50 cases (1989-2014).
Vet Comp Oncol. 15 (3): 1101-14.
Borthwick, C.R. et al. (2019) An Examination of the Development and Localization of Key Immune Cells in Developing Pouch Young of the Red-Tailed Phascogale (Phascogale calura).
Anat Rec (Hoboken). 302 (11): 1985-2002.
Tilly, H. et al. (2019) Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
The Lancet Oncology. 20 (7): 998-1010.
Sehn, L.H. et al. (2020) Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
J Clin Oncol. 38 (2): 155-65.
Herrera, A.F. et al. (2022) Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study.
Clin Cancer Res. Jan 03 [Epub ahead of print].
Piriou-Guzylack, L. (2008) Membrane markers of the immune cells in swine: an update.
Vet Res. 39: 54.
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.Yes, sign me up